Vericel Corporation | Advanced cell therapies

Product illustration

Now Approved: Arthroscopic Delivery of MACI

Get more info about MACI Arthro View MACI Arthro animation

Innovative Treatments

Explore our unique life-enhancing therapies

Patient Testimonials

See what people are saying about our therapies

Join Our Team

Find out about a career at Vericel

Vericel manufactures and markets two advanced cell therapy products for sports medicine and severe burn care in the United States and holds an exclusive license for North American commercial rights to NexoBrid^®, a biological orphan product approved for eschar removal of severe thermal burns. Please use the links to the right to visit our product websites and learn more about our pipeline.

InnovationRx: Regrowing Cartilage To Fix Damaged Knees And Ankles

InnovationRx: Regrowing Cartilage To Fix Damaged Knees And Ankles

by Forbes InnovationRx | October 23, 2024

Persistent knee pain is sometimes caused by damage to the cartilage that lines the end of the bones that form the knee. That damage can be caused by injury or just result from wearing down over time. One potential treatment for this is MACI, offered by Vericel...

First patient treated arthroscopically using Vericel’s custom designed MACI Arthro™ instrumentation

First patient treated arthroscopically using Vericel’s custom designed MACI Arthro™ instrumentation

by LinkedIn | August 29, 2024

We are proud to announce that the first patient was recently treated arthroscopically using Vericel-designed MACI Arthro™ instrumentation. The first MACI Arthro procedure was performed by Dr. Michael Banffy at the Cedars-Sinai Kerlan-Jobe Institute in Los Angeles and represents a significant milestone in our strategy to provide innovative solutions for adult patients suffering from cartilage defects in the knee...

FDA approves Vericel’s Maci for knee cartilage defects

FDA approves Vericel’s Maci for knee cartilage defects

by BioWorld | August 26, 2024

Vericel Corp.’s Maci for repairing cartilage defects in the knee has been approved by the U.S. FDA via a supplemental biologics license application. Using a patient’s own cells cultured on a porcine collagen membrane, Maci Arthro is delivered arthroscopically and allows for repair of knee cartilage defects up to 4 cm2...

Vericel receives FDA approval for arthroscopic MACI delivery

Vericel receives FDA approval for arthroscopic MACI delivery

by Healio | August 26, 2024

Vericel has received FDA approval to expand its MACI label to include MACI Arthro, an arthroscopic delivery of MACI to repair symptomatic knee cartilage defects, according to a company press release...

FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects

FDA Approves Arthroscopic Delivery of Vericel’s MACI for Knee Cartilage Defects

by PharmExec | August 26, 2024

The FDA has approved Vericel Corporation’s MACI for repairing cartilage defects in the knee. According to the company, MACI uses a patient’s own cells cultured on a porcine collagen membrane. This method, also known as MACI Arthro, can be administered through small incisions using custom instruments, providing a substantial improvement in full-thickness cartilage defects up to 4 cm² in size, offering a less invasive option, according to the company...

FDA approves pediatric indication for NexoBrid for treatment of thermal burns

FDA approves pediatric indication for NexoBrid for treatment of thermal burns

by Healio | August 20, 2024

The FDA has approved a pediatric indication for NexoBrid for the treatment of deep partial-thickness and full-thickness thermal burns, Vericel Corporation announced in a press release...

FDA approves anacaulase-bcdb for pediatric severe thermal burn patients

FDA approves anacaulase-bcdb for pediatric severe thermal burn patients

by Contemporary Pediatrics | August 20, 2024

A pediatric indication for anacaulase-bcdb (NexoBrid; MediWound Ltd) has been approved by the FDA for eschar removal in deep partial- and/or full-thickness thermal burn patients aged newborn to 18 years, according to a press release from MediWound Ltd...

NexoBrid Approval Expanded to Include Pediatric Burn Patients

NexoBrid Approval Expanded to Include Pediatric Burn Patients

by Medical Professionals Reference (MPR) | August 16, 2024

The Food and Drug Administration (FDA) has expanded the approval of NexoBrid (anacaulase-bcdb) to include eschar removal in pediatric patients aged newborn through 18 years with deep partial- and/or full-thickness thermal burns...

The Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave.

The Cell Therapy Market Is Expected To Grow 600% Over The Next Decade. This Biotech Is Poised To Capitalize On That Wave.

by Investor's Business Daily | August 7, 2024

Over the last decade, cell therapies have attracted a lot of investor attention to biotechs. These groundbreaking treatments use a patient's own cells to create personalized medicine that not only improves wellness outcomes for people, but it has the ability to transform the health care and pharmaceutical industries...

Load More

Company Presentation

Vericel Company Presentation

Download the PDF